DapaTAVI: dapagliflozin in patients undergoing transcatheter aortic valve implantation

31 August 2025 (09:09 - 09:27)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Borja Ibanez

National Centre for Cardiovascular Research CNIC AND Fundacion Jimenez Diaz Hospital, Madrid (Spain)

4 More presentations in this session

Presentation thumbnail

FLAVOUR II: angiography-derived fractional flow reserve vs. intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease

Professor B. Koo (Seoul, KR)

Presentation thumbnail

ECLIPSE: orbital atherectomy vs. balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies

Doctor P. Genereux (Morristown, US)

Presentation thumbnail

COMPARE-TAVI 1: SAPIEN 3 vs. Myval transcatheter heart valves for transcatheter aortic valve implantation

Doctor A. Eftekhari (Aalborg, DK)

Presentation thumbnail

A year in review: key trials in coronary and structural interventions shaping guidelines and patient care - discussion

Access the full session

Session thumbnail

A year in review: key trials in coronary and structural interventions shaping guidelines and patient care

The Event

Event poster

ESC Congress 2025

31 August 2025 09:09 CET

You may be interested in

Congress Presentation

Impact of dapagliflozin in quality of life of patients with aortic stenosis undergoing transcatheter aortic valve implantation

Congress Presentation

DAPA-MI – rationale and innovative design for a registry-based randomised clinical trial

Congress Presentation

Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources